Island Pharmaceuticals Limited (ASX: ILA) - Share Price
Current share price for ILA : $0.370 0.005 (1.37%)+
Island Pharmaceuticals Limited (ILA), an ASX-listed company, is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.
ILA General Information +
| ASX Code | ILA |
| Website | http://www.islandpharmaceuticals.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 109 |
| ILA Share Price | $0.370 |
| Day High | $0.380 |
| Day Low | $0.365 |
| Last Close | $0.365 |
| ILA Share Price Movement | $0.01 ( 1.37% ) |
Prices as at 16:40, 23 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Island Pharmaceuticals Limited (ILA) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Final | 10¢ | 0% | 23 Nov 1987 | 18 Dec 1987 | - | - | - |
| Interim | 3¢ | 0% | 26 May 1986 | 19 Jun 1986 | - | - | - |
| Final | 4¢ | 0% | 21 Oct 1985 | 15 Nov 1985 | - | - | - |
See all dividends from Island Pharmaceuticals Limited (ILA) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Island Pharmaceuticals Limited (ILA) price-sensitive announcements
ILA - FDA Grants Orphan Designation for Galidesivir in Marburg
Island Pharmaceuticals Limited announced that the US FDA has granted Orphan Drug Designati
Island Pharmaceuticals Limited (ILA)
17 Jun 2026 | 8:54 AM
17 Jun 2026 | 8:54 AM
ILA - Investor Presentation - Asia Dengue Summit
Island Pharmaceuticals Limited, an Australian antiviral drug development company, presente
Island Pharmaceuticals Limited (ILA)
16 Jun 2026 | 9:58 AM
16 Jun 2026 | 9:58 AM
ILA - Investor presentation
Island Pharmaceuticals Limited is focused on advancing two clinical stage programs targeti
Island Pharmaceuticals Limited (ILA)
11 Jun 2026 | 9:46 AM
11 Jun 2026 | 9:46 AM
ILA - Island Secures USAMRIID Support for Galidesivir Study
Island Pharmaceuticals Limited announced an expansion of its Cooperative Research and Deve
Island Pharmaceuticals Limited (ILA)
10 Jun 2026 | 8:53 AM
10 Jun 2026 | 8:53 AM
Island Pharmaceuticals Limited (ILA) Recent ASX Announcements
ILA Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$3.92 | -$2.30 | -28.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$2.86 | -$3.20 | 2.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$2.83 | -$3.10 | 8.40% | 0.00 | 0.00 | 0.00% | 0.0% |
ILA Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $809M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Island Pharmaceuticals Limited (ILA) | $105M | -0.2871 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $1,615M | -0.7857 | 0.0743 | 1.2000 | 54.7486 | 50.9600 | 23.1636 | 0.00% | 0.00% | 0.00% |
ILA Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 12.00 | 0.00 |
| Market | 0.29 | 13.20 | 1.17 | 0.67 |
| Sector | 0.43 | 26.20 | 2.49 | 2.38 |
ILA Directors
| Name | Position | Start Date |
|---|---|---|
| Dr David Foster | Chief Executive Officer, Managing Director, Executive Director | 1 Oct 2020 |
| Mr Jason Alan Carroll | Non-Executive Chairman, Non-Executive Director | 2 Jul 2025 |
| Mr Christopher Ntoumenopoulos | Non-Executive Director | 19 Sep 2024 |
Island Pharmaceuticals Limited (ILA) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 3 Dec 2025 | CARROLL, Jason | Exercise | Options | 974,930 | $0.070 | $68,245.100 |
| 3 Dec 2025 | NTOUMENOPOULOS, Christopher | Buy | Indirect Shares | 844,568 | $0.070 | $59,119.760 |
| 3 Dec 2025 | CARROLL, Jason | Buy | Direct Shares | 974,930 | $0.070 | $68,245.100 |
See all changes in directors' interest & trades for Island Pharmaceuticals Limited (ILA) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
ILA Management
| Name | Position |
|---|---|
| Cameron Jones | Chief Financial Officer,Company Secretary |
ILA Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Island Pharmaceuticals Limited (ILA). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 41,690,073 (16.86%) | William James Garner |
| 31,100,000 (12.58%) | Jason Alan Carroll |
| 19,264,773 (8.25%) | MWP Partners Limited |
| 14,010,000 (5.67%) | Daniel Tillett |
ILA Calendar of Events
| Date | Event |
|---|---|
| 24 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
